Cited by 30Histone Deacetylase Inhibitors ResearchPharmacogenetics and Drug MetabolismEnzyme function and inhibition

A Metabolic Screening Study of Trichostatin A (TSA) and TSA-Like Histone Deacetylase Inhibitors in Rat and Human Primary Hepatocyte Cultures

Elaut, G., Laus, G., Alexandre, E., Richert, L., Bachellier, P., Tourwé, D., Rogiers, V., Vanhaecke, T.·2007·The Journal of Pharmacology and Experimental Therapeutics

Abstract

Hydroxamic acid (HA)-based histone deacetylase (HDAC) inhibitors, with trichostatin A (TSA) as the reference compound, are potential antitumoral drugs and show promise in the creation of long-term primary cell cultures. However, their metabolic properties have barely been investigated. TSA is rapidly inactivated in rodents both in vitro and in vivo. We previously found that 5-(4-dimethylaminobenzoyl)aminovaleric acid hydroxyamide or 4-Me2N-BAVAH (compound 1) is metabolically more stable upon incubation with rat hepatocyte suspensions. In this study, we show that human hepatocytes also metabolize TSA more rapidly than compound 1 and that similar pathways are involved. Furthermore, structural analogs of compound 1 (compounds 2-9) are reported to have the same favorable metabolic properties. Removal of the dimethylamino substituent of compound 1 creates a very stable but 50% less potent inhibitor. Chain lengthening (4 to 5 carbon spacer) slightly improves both potency and metabolic stability, favoring HA reduction to hydrolysis. On the other hand, Calpha-unsaturation and spacer methylation not only reduce HDAC inhibition but also increase the rate of metabolic inactivation approximately 2-fold, mainly through HA reduction. However, in rat hepatocyte monolayer cultures, compound 1 is shown to be extensively metabolized by phase II conjugation. In conclusion, this study suggests that simple structural modifications of amide-linked TSA analogs can improve their phase I metabolic stability in both rat and human hepatocyte suspensions. Phase II glucuronidation, however, can compensate for their lower phase I metabolism in rat hepatocyte monolayers and could play a yet unidentified role in the determination of their in vivo clearance.

Integrity signals

Registry

Crossref · 10.1124/jpet.106.116202

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

1 of the 36 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Elaut, G., Laus, G., Alexandre, E., Richert, L., Bachellier, P., Tourwé, D., Rogiers, V., & Vanhaecke, T.
Affiliations
Vrije Universiteit Brussel (BE)
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
2007-04
Volume
321
Issue
1
Pages
400-408
ISSN
0022-3565 (ISSN-L)
OpenAlex
W2138147574
Cited by
26
References
36
Citations by year
2024: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2016: 2 · 2014: 3 · 2013: 2 · 2012: 2
FWCI
1.59
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
Keywords
trichostatin A, histone deacetylase inhibitors, hydroxamic acid derivatives, drug metabolism, metabolic stability, primary hepatocytes, human hepatocytes, rat hepatocytes, phase I metabolism, structural analogues, hydrolysis, anticancer agents, drug clearance
MeSH terms
Animals, Biotransformation, Cell Membrane, Cell Separation, Cells, Cultured, Chromatography, High Pressure Liquid, Enzyme Inhibitors, Humans, Hydroxamic Acids, Indicators and Reagents, Male, Spectrophotometry, Ultraviolet, Rats, Sprague-Dawley, Hepatocytes, Rats, Histone Deacetylase Inhibitors, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review